Proceeds to support continued clinical development of ontivatrep, an oral TRPV3 inhibitor, with Phase 1b topline results in Olmsted syndrome expected by the end of 2026

所得款项将用于支持口服TRPV3抑制剂ontivatrep的持续临床开发，预计将于2026年底前公布其在奥姆斯特德综合征（Olmsted syndrome）中的1b期临床试验顶线结果。

NESS ZIONA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) --

以色列内斯锡奥纳，2026年9月15日（环球新闻社）--

Orvida

奥维达

Pharma

制药

, a clinical-stage biotechnology company developing first- and best-in-class treatments for rare and severe genetic skin diseases, today announced the completion of an interim financing led by Recordati, a global pharmaceutical group headquartered in Milan, Italy, with a dedicated Rare Diseases business, alongside continued participation from Orvida’s existing shareholders..

，一家专注于为罕见且严重的遗传性皮肤病开发首创和同类最佳疗法的临床阶段生物技术公司，今日宣布完成由总部位于意大利米兰、设有专属罕见病业务部门的全球制药集团Recordati领投的 interim 融资，Orvida的现有股东也继续参与跟投。

The financing provides additional resources to support the continued development of Orvida’s lead investigational therapy, ontivatrep (formerly KM-023), a highly specific and selective oral TRPV3 inhibitor. The financing will also support the advancement of the Company’s broader pipeline of programs in additional rare genetic skin disease indications..

此次融资提供了额外资源，以支持Orvida公司主要研究性疗法ontivatrep（前身为KM-023）的持续开发，这是一种高度特异性和选择性的口服TRPV3抑制剂。该融资还将支持公司更广泛的产品管线在其它罕见遗传性皮肤病适应症方面的推进。

“We are very pleased to welcome Recordati as an investor in Orvida and grateful for the continued support of our existing shareholders,” said David Aviezer, PhD, MBA, Chief Executive Officer of Orvida Pharma. “Recordati’s investment brings an important new pharmaceutical investor to Orvida and strengthens our ability to advance ontivatrep as we approach an important milestone: the first clinical data from patients with Olmsted syndrome.

“我们非常高兴欢迎Recordati成为Orvida的投资者，并感谢现有股东的持续支持，”Orvida Pharma首席执行官David Aviezer博士（MBA）表示。“Recordati的投资为Orvida引入了一位重要的新制药投资者，并增强了我们推进ontivatrep的能力，因为我们正接近一个重要的里程碑：获得来自Olmsted综合征患者的首批临床数据。”

With favorable Phase 1a safety data supporting the program and ontivatrep now being evaluated in patients for the first time, we are focused on delivering the clinical data needed to guide its continued development. We look forward to building on this momentum and working toward advancing a potential new treatment option for patients living with Olmsted syndrome.”.

鉴于有利的1a期安全性数据为本项目提供了支持，且ontivatrep首次在患者中进行评估，我们正专注于提供指导其持续开发所需的临床数据。我们期待在此基础上再接再厉，致力于推进为奥姆斯特德综合征患者提供一种潜在的新治疗选择。

Ontivatrep is being developed for Olmsted syndrome, severe keratodermas and ichthyosis, rare genetic skin diseases characterized by significant unmet medical need. Olmsted syndrome is a rare and severe genetic skin disorder that causes painful, thickened skin, particularly on the palms and soles, and can significantly impair mobility and quality of life and, in some cases can be life-threatening.

Ontivatrep 正在开发用于治疗奥尔姆斯特德综合征、严重角化病和鱼鳞病，这些罕见的遗传性皮肤病存在巨大的未满足医疗需求。奥尔姆斯特德综合征是一种罕见且严重的遗传性皮肤病，会导致皮肤疼痛性增厚，尤其见于手掌和足底，可能严重损害行动能力和生活质量，在某些情况下甚至危及生命。

There are currently no approved therapies for Olmsted syndrome..

目前尚无针对奥尔姆斯特德综合征的获批疗法。

In April 2026, Orvida reported

2026年4月，Orvida报告称

favorable Phase 1a safety data

良好的1a期安全性数据

for ontivatrep from a randomized, placebo-controlled study in 40 healthy volunteers. The Company has since initiated the Phase 1b clinical trial in patients with Olmsted syndrome in Europe and the U.S. The study is designed to evaluate the safety, tolerability and pharmacokinetics of ontivatrep, as well as exploratory measures of clinical activity, following 12 weeks of twice-daily treatment.

来自一项在40名健康志愿者中开展的随机、安慰剂对照研究的ontivatrep数据。此后，公司已在欧洲和美国启动了针对奥尔姆斯特德综合征患者的1b期临床试验。该研究旨在评估每日两次、持续12周治疗后ontivatrep的安全性、耐受性和药代动力学，以及探索性临床活性指标。

Topline results are expected in the fourth quarter of 2026..

预计2026年第四季度将公布初步结果。

Orvida will deliver a corporate presentation during the BIO-Europe 2026 conference, taking place November 9–11, 2026, in Cologne, Germany, and will also participate in the Jefferies Global Healthcare Conference in London, November 16–19, 2026. The Company will be available for one-on-one meetings with investors and pharma companies at both conferences..

Orvida 将在2026年11月9日至11日于德国科隆举行的BIO-Europe 2026大会上发表企业演讲，并参加2026年11月16日至19日在伦敦举行的Jefferies全球医疗保健会议。在这两场会议上，公司将安排与投资者和制药公司进行一对一的会晤。

About Orvida Pharma

关于 Orvida Pharma

Orvida Pharma (formerly Kamari Pharma) is a clinical-stage biotechnology company developing first- and best-in-class treatments for rare and severe genetic skin diseases. The Company’s lead investigational candidate, ontivatrep, is a novel, highly specific, and selective oral TRPV3 inhibitor being developed for the treatment of Olmsted syndrome, severe keratodermas and ichthyosis.

Orvida Pharma（前身为 Kamari Pharma）是一家处于临床阶段的生物技术公司，致力于开发针对罕见且严重的遗传性皮肤病的首创和同类最优疗法。公司的主要候选药物 ontivatrep 是一种新型、高特异性且高选择性的口服 TRPV3 抑制剂，正在开发用于治疗 Olmsted 综合征、严重角化病和鱼鳞病。

Orvida’s management team comprises industry leaders with deep expertise in drug discovery, dermatological pharmaceutical development, and rare disease therapeutics..

Orvida的管理团队由在药物发现、皮肤科药物开发和罕见病治疗领域拥有深厚专业知识的行业领袖组成。

About

关于

Recordati

雷科达蒂

Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. The group is uniquely structured to provide treatments across Specialty & Primary Care, Consumer Healthcare and Rare Diseases.

Recordati 是一家在意大利证券交易所上市（XMIL: REC）的国际制药集团，其渊源可追溯至20世纪20年代意大利北部的一家家族经营药店。该集团采用独特的架构，提供涵盖专科与初级保健、消费者健康以及罕见病领域的治疗产品。

Its fully integrated operations span clinical development, manufacturing of active ingredients and finished products, commercialization and licensing. Recordati operates in approximately 150 countries across EMEA, the Americas and APAC, with around 4,700 employees..

其完全整合的业务涵盖临床开发、原料药和成品生产、商业化及许可。Recordati 在 EMEA（欧洲、中东和非洲）、美洲和亚太地区约 150 个国家开展业务，拥有约 4,700 名员工。

Contact Information

联系方式

Investors and Media

投资者与媒体

Marcy Nanus

马西·纳努斯

Managing Partner

管理合伙人

Trilon Advisors, LLC

Trilon Advisors, LLC

mnanus@trilonadvisors.com

mnanus@trilonadvisors.com